To read the final rule and additional information about PSOs

To read the final rule and additional information about PSOs, including background on the legislative process,FDA 510 Clinical Trial Progress for AppyScore, World First Blood – Based Diagnostic Test For Human Appendicitis – As announced in our press release at October 2008 discussed the promotion AppyScore and the current FDA application for our 45 minutes ELISA lab test is the company’s number one priority. In addition the company is in order to make progress on two additional formats of the appendicitis test in its product pipeline . The two additional versions of the test, now in formal GMP development are designed so that approximately three times faster, which results in about 15 minutes and are less labor-intensive. AspenBio Pharma president and CEO, Richard Donnelly, stated, Upon completion of of this 800 patient trial and achieving FDA 510 clearance of our AppyScore appendicitis blood test, the primary focus of the company during the actual date of completion of the study study is too short, at current prices, we are now only a few weeks of enrollment, which is exciting. .

This press release contains forward-looking statements of AspenBio Pharma as of the Securities and Exchange Commission defines. All statements, other than statements of historical facts arise that in the press release that address activities, events or developments that APPY APPY or expected or could in the future are forward-looking statements. These statements are based on certain assumptions based on experience, expected future developments and believes other factors APPY, are appropriate in the circumstances. Such statements are involve a number of assumptions, risks and uncertainties, many of which are beyond the control of APPY. Investors are cautioned that. Such statements are not guarantees of future performance Actual results or developments may differ materially projected from those in the forward-looking statements required as a result of many factors, including statements regarding the ability to to successfully complete the clinical studies and clinical trials for the FDA submission, FDA approval received for, inexpensive to produce and generate revenues from the appendicitis test as well as the animal products under this agreement and other new products, agreements lead successfully promote successfully promote the objectives of the company, retain the scientific management team in order to promote the products, overcome adverse changes in market conditions and the regulatory environment, fluctuations in obtaining the volumes, and intellectual property rights and realization of intangible assets. Furthermore, APPY does not intend update publicly any update publicly any forward-looking statements. The content of this press together with the together with the included warnings, and advisories in the last filings with the SEC APPY.

Source Vertex Pharmaceuticals IncorporatedTwo clinical trials at the week New England Journal of Medicine show blood infections the investigational orally hepatitis C virus protease inhibitors telaprevir metered into combination with pegylated interferon and ribavirin introduced as part of an 24-week treatment regime of in a significant improvement of the rate of sustained viral appeal , Why – treating as a cure of the virus infection , in which? Pack genotype 1 HCV patient, how compared with SVR of standard treatment for 48 weeks administered. The data come from two initial 2b clinical trials of telaprevir as a PROVE 1 and PROVE 2 famous. In these studies, patients who received a 24-week of telaprevir based treatment reach SVR rates of up to 69 %, comparison having speeds of up to 46 per cent patients receiving control of these trials, which peg-IFN SAR and RBV to a default term of 48 weeks. In partnership with Tibotec will and Mitsubishi Tanabe Pharma: Telaprevir is developed by Vertex Pharmaceuticals Incorporated . Telaprevir is currently in Phase 3 clinical development.

PROVE 2 trial style? PROVE 2 was a Phase 2 b, randomized, partially double-blind, placebo-controlled study, and wrote to dealt three hundred twenty-three treatment -na. Pack genotype 1 HCV patients at 28 centers in France, Germany, the UK and Austria By patients enrolled in PROVE 2, the mean age was 44.4 % were men of and 94.1 % were white with. Patients in PROVE 2 received 750mg of telaprevir administered orally q8h, based upon of the treatment arms, a once – week 180ug injecting Peginterferon alfa-2a, and an 1,000 mg or 1 more than 2200 mg in weight based daily oral dose of ribavirin. PROVE 2 was composed treating a 24-week telaprevir based arm of made 12 weeks telaprevir in conjunction with PEG-IFN and RBV order 12 weeks peg-IFN and ribavirin alone accepted, a 12 – weeks telaprevir -based arm of consisting a 12 week of telaprevir used in combination with PEG-IFN and RBV a 12-week of telaprevir based branch consisting a 12 week telaprevir used in combination with PEG-IFN , and one control arm from 12 weeks placebo in combination with PEG-IFN and RBV in order to 36 weeks of peg-IFN and RBV solely follow.